Free Trial
→ Before you buy SpaceX shares, consider this alternative approach (From Weiss Ratings) (Ad)tc pixel
NASDAQ:ANAB

AnaptysBio Q1 2026 Earnings Report

AnaptysBio logo
$68.81 +1.85 (+2.76%)
As of 01:41 PM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

AnaptysBio EPS Results

Actual EPS
N/A
Consensus EPS
-$0.64
Beat/Miss
N/A
One Year Ago EPS
N/A

AnaptysBio Revenue Results

Actual Revenue
N/A
Expected Revenue
$18.86 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

AnaptysBio Announcement Details

Quarter
Q1 2026
Date
5/11/2026
Time
Before Market Opens
Conference Call Date
Friday, May 15, 2026
Conference Call Time
4:00PM ET

Conference Call Resources

AnaptysBio Earnings Headlines

Piper Sandler Releases a Buy Rating on AnaptysBio (ANAB)
May 5 at 7:59 PM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/ANAB/pressreleases/1706747/piper-sandler-releases-a-buy-rating-on-anaptysbio-anab/
Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference
May 4, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/04/3287160/0/en/anaptys-to-participate-at-the-h-c-wainwright-2nd-annual-royalty-company-virtual-conference.html
The chokepoint supplier behind SpaceX's $1.75 trillion empire
Colossus is expanding from 100,000 GPUs to 1 million - a buildout that costs north of $50 billion and depends entirely on getting power infrastructure built fast enough. Lead times on heavy power equipment have stretched to 120+ weeks. One small company has built its reputation on speed and is sitting on a $1.5 billion backlog. When the SpaceX-xAI S-1 drops in June, this dependency becomes visible to everyone.tc pixel
May 8 at 1:00 AM  |  Behind the Markets (Ad)
AnaptysBio (ANAB) Is Up 13.4% After Court Upholds Jemperli Royalty Rights In Tesaro Dispute
May 3, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/anaptysbio-anab-13-4-court-011209386.html
Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence
April 28, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-the-publication-of-efficacy-and-safety-of-imsidolimab-for-generalized-pustular-psoriasis-in-nejm-evidence-302756392.html
GSK subsidiary Tesaro, AnaptysBio provide update on contract claim litigation
April 27, 2026  |  msn.comhttps://www.msn.com/en-us/money/other/gsk-subsidiary-tesaro-anaptysbio-provide-update-on-contract-claim-litigation/ar-AA21PYRa
See More AnaptysBio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like AnaptysBio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on AnaptysBio and other key companies, straight to your email.

About AnaptysBio

AnaptysBio (NASDAQ:ANAB) is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company's technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders. Among its leading candidates is ANB020, an anti-IL-33 antibody being evaluated for atopic dermatitis and eosinophilic asthma, and ANB019, an anti-IL-36 receptor antibody in development for generalized pustular psoriasis. In addition to its clinical assets, AnaptysBio is advancing several preclinical programs aimed at novel immuno-oncology targets, reflecting its commitment to broadening the therapeutic potential of its platform.

AnaptysBio has established strategic partnerships to enhance its research and development efforts. These collaborations include agreements with major pharmaceutical companies to co-develop and commercialize select antibody candidates. Through these alliances, AnaptysBio gains access to expanded development expertise, global regulatory capabilities, and commercialization support, while retaining rights to key programs emerging from its discovery engine.

Since completing its initial public offering in 2016, AnaptysBio has grown its team and infrastructure to support both early-stage discovery and late-stage clinical development. The company is led by President and Chief Executive Officer Hamza Suria and maintains research operations in the United States. AnaptysBio’s mission is to deliver differentiated antibody therapeutics that address unmet medical needs in inflammatory diseases and cancer.

View AnaptysBio Profile
Earnings Tools